---
title: "Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis. Clinical evidence covers NATiV3, NATIVE, LEGEND, and NCT03459079. 772 evidence topics quoted from 220 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Lanifibranor

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

<a id="topic-1.1.1-1"></a>

##### Summary: definition, etiology, and diagnosis

Under the revised nomenclature, metabolic dysfunction-associated steatotic liver disease (MASLD) replaced nonalcoholic fatty liver disease (NAFLD), chosen by 75% of respondents of the external expert committee, and metabolic dysfunction-associated steatohepatitis (MASH) replaced nonalcoholic steatohepatitis (NASH), chosen by 88%. MASLD is defined as hepatic steatosis with at least one cardiometabolic risk factor and no other discernible cause. Disease staging is unchanged, and 98% of a European registry cohort with NAFLD fulfilled the MASLD criteria; in a US national study, 99.0% (95% CI 97.6% to 99.6%) of adults with NAFLD or MASLD met the criteria for both. The 2023 AASLD practice guidance defines at-risk NASH as biopsy-proven NASH with stage 2 or higher fibrosis. The European Association for the Study of the Liver (EASL) guideline names type 2 diabetes and obesity as the metabolic diseases with the strongest impact on progression to advanced fibrosis, cirrhosis, and hepatocellular carcinoma, and identifies the PNPLA3 p.I148M and TM6SF2 p.E167K variants as major risk factors; the heritable component of NAFLD and NASH is estimated at 35% to 61%.

NAFLD is asymptomatic or associated with vague symptoms in most patients, and patients are most commonly referred with incidentally noted hepatic steatosis on imaging or elevated liver chemistries. In US cross-sectional surveys of physicians and consulting patients with suspected or confirmed MASH in 2019 and 2022, no sign or symptom was reported for 167 patients (39.4%) overall; fatigue was reported for 230 (54.2%) overall and for 70 (85.4%) in the AASLD-derived high-risk category.

Liver biopsy is the reference standard for grading and staging but has limitations related to risk, cost, and resource utilization, and none of the noninvasive methods can assess ballooning or lobular inflammation. Guidelines use a fibrosis-4 index (FIB-4) below 1.3 to identify low risk, with follow-up in primary care, and FIB-4 of 1.3 or higher to prompt secondary assessment with vibration-controlled transient elastography (VCTE) or the Enhanced Liver Fibrosis (ELF) test; FIB-4 above 2.67 indicates high risk, and the EASL guideline states that FIB-4 will miss around 10% of individuals with advanced fibrosis. A VCTE liver stiffness below 8 kPa can rule out advanced fibrosis, and above 12 kPa is associated with a high likelihood of advanced fibrosis. Aminotransferase levels are frequently normal in advanced disease. The AASLD guidance updates state that no FDA-approved noninvasive test diagnoses MASH with F2 to F3 or monitors response, that the resmetirom label does not require biopsy, and that semaglutide candidates with stage 2 to 3 fibrosis can be identified by VCTE (8 to 15 kPa), magnetic resonance elastography (3.1 to 4.4 kPa), or ELF (9.2 to 10.5).

Diagnosis rates are low. A US population calculator cites a diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population, and NHANES survey responses indicate that 14.3% of prevalent patients with F2 to F3 NASH have received a diagnosis of liver disease. The 2016 prevalence of diagnosed NASH among US adults was 0.15%. In NHANES 2017 to 2023, awareness of liver disease was 5.8% (pre-pandemic) and 6.7% (late pandemic) among adults with MASLD, and 12.1% and 10.3% among adults with MASLD and liver stiffness of 8 to 15 kPa.

Source: [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/); [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/); [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext); [Loomba et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12168897/); [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated); [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated); [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/); [Alp et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12520227/)

<a id="topic-1.1.1-2"></a>

##### Summary: US prevalence and incidence

Estimates differ by the population counted, the definition, and the method:

- Steatotic liver disease and MASLD, US adults, national study: steatotic liver disease 34.2% (more than 90 million US adults), MASLD 31.3%. In NHANES 2017 to 2023, the age-adjusted prevalence of MASLD was 31.9%.
- MASLD by liver stiffness: of 2,691 NHANES 2017 to 2020 participants with MASLD, projecting to 75.8 million US adults, 11% had liver stiffness of 8 to 12 kPa and 6% of 12 kPa or higher.
- At-risk NASH (NAFLD activity score of 4 or more and fibrosis stage 2 or higher, estimated by FibroScan-AST score above 0.35): overall prevalence 11.6% (95% CI 8.8 to 15.1), higher in males than in females (15.8% and 6.5%); the authors estimated ~9 million people in the US have at-risk NASH.
- Adults meeting resmetirom eligibility criteria defined by ALT, controlled attenuation parameter, and liver stiffness: 8.3 million (liberal criteria) and 2.3 million (restrictive criteria).
- Adults aged 50 years or older with type 2 diabetes in a southern California cohort, 2016 to 2023: MASLD 69.6%, at-risk MASH 13.6%, cirrhosis 6.8%.
- Modeled NASH with F2 to F3 fibrosis: an eligible-population model applied a NASH prevalence of 4.6% (range 1.3% to 14.2%) and a non-cirrhotic F2 to F3 proportion of 35%, yielding 1,255 to 1,699 treatment-eligible patients per 1 million commercial members in Years 1 to 3. The ICER budget impact analysis applied a prevalence of 1.4% to US adults aged 18 and older (4% NASH multiplied by 35% with moderate to severe fibrosis), an average of 3.81 million eligible patients.
- Modeled trends: one model projected cases of MASH with F2 or higher fibrosis to increase from 6.7 million in 2020 to 11.7 million by 2050, and MASH cases from 14.9 million (5.8% of US adults) to 23.2 million (7.9%). Another projected NASH cases to increase from 16.52 million in 2015 to 27.00 million in 2030, with NASH with F3 to F4 fibrosis increasing from approximately 3.31 million (20% of NASH cases) to 7.94 million (29%). A third estimated 6.65 million US adults with NASH and 232,000 incident cases in 2017.
- Incidence: one analysis projected 73,085 newly coded US patients with F2 to F3 NASH in 2020, a rate of 28.4 cases per 100,000 adults (other analyses 20.4 to 64.0 per 100,000 adults). Across 54 studies, 31% of patients developed NASH after 4.7 years (7.4 per 100 person-years).

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/); [Kim et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12016658/); [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/); [Payne et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9833447/); [Le et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180822/); [Mittal et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12425555/); [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [Le et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742522/); [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/); [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/); [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)

<a id="topic-1.1.1-3"></a>

##### Summary: natural history and mortality by fibrosis stage

Fibrosis and steatohepatitis are the primary predictors of progression, and patients with NASH and at least stage 2 fibrosis have a higher risk of liver-related morbidity and mortality. In 14 articles of cohort studies involving 17,301 patients with biopsy-proven NAFLD, all-cause mortality hazard ratios compared with stage 0 were 1.46 for stage 2, 1.96 for stage 3, and 3.66 for stage 4, and liver-related mortality hazard ratios were 4.07, 7.59, and 15.1. Among 1,495 patients with NAFLD (17,452 patient years of follow-up), mortality rate ratios for stages 2 and 3 were 2.52 and 3.48 for all-cause mortality and 9.57 and 16.69 for liver-related mortality. Among 1773 adults with NAFLD followed for a median of 4 years, all-cause mortality was 0.32 deaths per 100 person-years for F0 to F2, 0.89 for F3, and 1.76 for F4, and any hepatic decompensation event was associated with increased all-cause mortality (adjusted hazard ratio 6.8). In a cohort of 1,260 patients with NAFLD without cirrhosis followed for a median of 13 years, the 20-year cumulative incidence of major adverse liver outcomes was 3% for F0 and 35% for F3, with adjusted hazard ratios of 2.9 for biopsy-determined F2 and 8.9 for F3 compared with F0 to 1. In a cohort analysis supported by Novo Nordisk Inc., incidence rates of cirrhosis were 0.34/100PM for F0 to F1, 1.24/100PM for F2 (281 patients), and 6.62/100PM for F3 (162 patients), and all-cause mortality rates were 0.14, 0.3, and 0.42/100PM.

A pooled analysis of 54 studies estimated the time to progress by one fibrosis stage at 13.3 years from F2 and 22.2 years from F3; after 5 years, 32% of patients with F2 progressed, 37% regressed, and 31% remained stable, and patients with F3 regressed more often than they progressed (32% and 22%). In a Swedish nationwide cohort of 10,568 individuals with biopsy-confirmed NAFLD, non-cirrhotic fibrosis was associated with excess mortality compared with controls (18.4/1000PY, aHR 2.44), and the excess mortality was primarily from extra-hepatic cancer. Cardiovascular disease and nonhepatic malignancy are the most common causes of death in NAFLD, followed by liver disease. One projection estimated that NAFLD-related incident decompensated cirrhosis would increase from 39,320 cases in 2015 to 105,430 in 2030, incident hepatocellular carcinoma from 5,160 to 12,240, and liver deaths to 78,300 in 2030. According to CDC FastStats, chronic liver disease and cirrhosis of all causes accounted for 52,274 US deaths (15.4 per 100,000 population), the ninth-ranked cause of death.

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/); [Dulai et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5397356/); [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/); [Akbari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10827505/); [Luthra and Sheth (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11787050/); [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/); [Simon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185553/); [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/); [CDC FastStats chronic liver disease and cirrhosis (2026)](https://www.cdc.gov/nchs/fastats/liver-disease.htm)

<a id="topic-1.1.1-4"></a>

##### Summary: long-term morbidity

The prevalence of cirrhosis in the United States is 2.6%, and individuals with MASLD comprise the majority of US residents with cirrhosis (MASLD-cirrhosis 1.27% of the general population). Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year. In the cohort of 1773 adults with NAFLD, incidence per 100 person-years for F0 to F2, F3, and F4 was 0.04, 0.52, and 1.20 for ascites, 0.02, 0.75, and 2.39 for encephalopathy, and 0.04, 0.34, and 0.14 for hepatocellular cancer. Among 296,707 US veterans with NAFLD, hepatocellular carcinoma incidence was 0.21/1000 PY compared with 0.02/1000 PY in matched controls (hazard ratio 7.62), and 20% of patients with NAFLD and hepatocellular carcinoma had no evidence of cirrhosis; across 61 studies, 38.5% of NAFLD-related hepatocellular carcinoma occurred without cirrhosis. The EASL guideline states that individuals with F3 fibrosis have an intermediate risk of hepatocellular carcinoma and that surveillance may be considered for them. NASH/MASH increased from 9% to 28% of US liver transplant recipients from 2000 to 2022, and 44.5% of 65,675 US adults on the liver transplant waitlist for steatotic liver disease from 2010 to 2023 had MASH.

NAFLD was associated with an increased risk of fatal or non-fatal cardiovascular events (pooled HR 1.45), which increased with fibrosis stage (pooled HR 2.50), and with incident chronic kidney disease (HR 1.43). In the cohort of 1773 adults with NAFLD, new-onset hypertension (7.8 events per 100 person-years) and type 2 diabetes (4.8 events per 100 person-years) were the most common new nonhepatic outcomes. NAFLD was associated with a nearly 1.5-fold to twofold increased risk of gastrointestinal cancers.

Source: [Younossi et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/39879587/); [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/); [Kanwal et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6279617/); [Tan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9718369/); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext); [Younossi et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/40674288/); [Patel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11869966/); [Mantovani et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34555346/); [Mantovani et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/33303564/); [Mantovani et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/33685968/)

<a id="topic-1.1.1-5"></a>

##### Summary: humanistic burden

In the 2016 US National Health and Wellness Survey, 136 adults with physician-diagnosed NASH reported lower mental (43.19 and 46.22) and physical (42.04 and 47.10) component scores than 544 matched adults from the general population, and higher proportions with anxiety (37.5% and 25.5%) and depression (43.4% and 30.1%). Among 713 adults with NAFLD in the NASH Clinical Research Network, physical health scores were 44.6 with moderate or bridging fibrosis and 38.4 with cirrhosis, and mental health scores did not differ by degree of fibrosis. Among 1667 adults with NASH and F3 or F4 fibrosis at baseline of the STELLAR trials, patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4 of 8 SF-36 domains compared with the general population; 33% and 27% of 1,669 patients had fatigue and pruritus.

In the GAIN study, mean EQ-5D index values in the United States were 0.80 for early (F0 to F2) and 0.67 for advanced (F3 to F4) fibrosis, and across all countries 0.80 and 0.62; mean CLDQ-NAFLD index values in the United States were 4.7 and 4.0. The baseline mapped EQ-5D utility of 800 participants with biopsy-confirmed MASH and F2 or F3 fibrosis in a trial of semaglutide 2.4 mg or placebo was ∼0.78, with group means of 0.783 and 0.789 for stage 2 and 0.792 and 0.769 for stage 3. In a phase 2 trial of 392 patients with bridging fibrosis or compensated cirrhosis, those with fibrosis improvement of at least one stage at week 48 had improvement in EQ-5D and five of six CLDQ-NASH domains. Across 25 publications covering 23 unique studies, all evaluable studies had inadequate control of confounders, and in a meta-analysis, three studies of increasing fibrosis and quality of life had inconsistent findings.

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/); [David et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2692572/); [Younossi et al. (2019b)](https://pubmed.ncbi.nlm.nih.gov/30779990/); [Younossi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7603531/); [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/); [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/); [Younossi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8279457/); [Younossi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9418497/); [Taylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32027911/)

<a id="topic-1.1.1-6"></a>

##### Summary: economic burden, caregiver costs, and diagnostic testing

Annual direct medical costs of NAFLD in the United States were estimated at about $103 billion ($1,613 per patient) for over 64 million people, and lifetime costs of all US patients with NASH in 2017 at $222.6 billion, of which $95.4 billion for the advanced NASH population. In the GAIN study of 3,754 patients with NASH in 2018, the mean total annual per-patient cost was €2,763 direct medical, €4,917 direct non-medical, and €5,509 indirect; NASH-related direct medical costs were €2,224 for early and €3,983 for advanced fibrosis (€4,881 in the USA), and indirect costs were €5,939 and €12,642. Professional (34%) and informal (48%) caregivers accounted for most direct non-medical costs, and these percentages increased with fibrosis stage; patient-reported non-medical costs were €1,704 for early and €4,661 for advanced fibrosis.

Modeled annual costs by health state differ by source. The ICER model used annual costs of $7,063 for F0 to F2, $8,423 for F3, $34,275 for compensated cirrhosis, $158,480 for decompensated cirrhosis, and $115,002 for hepatocellular carcinoma. A model funded by Siemens Healthcare Diagnostics Inc used annual direct medical costs (2025 USD) of $1,180 for F2-3, $23,360 for compensated cirrhosis, and $36,290 for decompensated cirrhosis.

In linked electronic health record and claims data, mean annual costs among 6,743 adults with NASH increased from $16,744 to $34,667 between the lowest and highest FIB-4 cohorts, and each one-unit increase in FIB-4 was associated with a 3.4% increase in mean total annual cost. Among 251,725 commercially insured adults, total all-cause costs increased by 17% to 29% after identification of FIB-4-based F3 fibrosis and by 47% to 48% for F4. Among 485,774 commercially insured adults with NAFLD or NASH, adjusted annual costs were $23,860 without advanced liver disease, $29,078 with compensated cirrhosis, $134,448 with decompensated cirrhosis, $197,392 with liver transplant, and $97,563 with hepatocellular carcinoma. Compared with the matched general population, adults with NASH reported more health care provider visits (8.43 and 5.17), hospitalizations (0.43 and 0.21), and overall work impairment (39.6% and 26.2%). One model estimated that a hypothetical therapy halting fibrosis progression in MASLD would avert $40.5 to $99.1B in incremental health care costs.

One prior authorization policy for resmetirom and semaglutide requires documentation of F2 or F3 fibrosis by liver biopsy within 3 years, VCTE or magnetic resonance elastography within 6 months, or an ELF score of 9.2 to 10.5 within 6 months. Unit costs in the diagnostics manufacturer-funded model were $200 for a one-time ELF screening test, $257 for a hepatology consultation, $32 for transient elastography, $323 for MRI or CT, and $354 for liver biopsy. When the current FIB-4-based guideline was applied to NHANES data, 18.1 million VCTE examinations would be needed to diagnose 3.5 million US adults with MASLD and liver stiffness of 8 kPa or higher. Among 8,366 primary care patients with type 2 diabetes or prediabetes, 2,064 (25%) had FIB-4 values needing confirmatory risk assessment, 9.1 times the number with a MASLD diagnosis. In a US modeling study, screening strategies for high-risk MASLD added $13,587 to $14,730 per patient with type 2 diabetes compared with no screening. In the GAIN study, 697 (57%) US patients had a liver biopsy and 157 (13%) received transient elastography.

Source: [Younossi et al. (2016b)](https://pubmed.ncbi.nlm.nih.gov/27543837/); [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/); [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/); [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/); [Tapper et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36866575/); [Gordon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7327220/); [Wong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8500367/); [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/); [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/); [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf); [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/); [Patel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094816/); [Younossi et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39373093/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Lanifibranor Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: regulatory status, NATiV3 design, and NATiV3 status

Lanifibranor is an investigational oral pan-PPAR agonist that “has not been approved for use by any regulatory authority”. The FDA granted Fast Track designation for NASH and Breakthrough Therapy designation for NASH in October 2020, and the Chinese NMPA granted Breakthrough Therapy designation for MASH in December 2023.

- Design: NATiV3 (NCT04849728) is a randomised, double-blind, placebo-controlled, multicentre phase 3 trial in adults with biopsy-proven noncirrhotic MASH and F2 or F3 fibrosis. Participants were randomized 1:1:1 to lanifibranor 800 mg or 1200 mg once daily or placebo for 72 weeks, stratified by fibrosis stage (F2, F3) and by presence or absence of type 2 diabetes. The registry record lists 459 locations.
- Enrollment: the company reports 1,009 participants in the main cohort and 410 in an exploratory cohort of participants with F1 through F4 fibrosis who were histologically not eligible for the main cohort. The registry gives an estimated enrollment of 1000, and the Form 20-F anticipates an NDA for accelerated approval based on liver histological endpoints of approximately 950 patients. In company slides, 67.0% of the main cohort had F3 fibrosis, 55% had type 2 diabetes, 14.0% were taking a GLP-1 receptor agonist, and 10.0% an SGLT2 inhibitor at baseline.
- Primary endpoint: the registry defines the primary outcome as resolution of NASH and improvement of fibrosis at week 72. Company materials name this composite as the primary endpoint and the two single histologic endpoints as key secondary endpoints, while the Form 20-F financing terms refer to “any key primary endpoint or key secondary endpoint of NATiV3 (resolution of NASH without worsening fibrosis and improvement of liver fibrosis without worsening NASH)”.
- Extension: the registry describes a 48-week “double-blind active treatment extension”, and the company's last patient visit release describes a “48-week open-label extension period” in which all participants, including those originally randomized to placebo, receive lanifibranor.
- Status: the company announced that the last participant completed the final 72-week visit and that all participants had completed the 72-week treatment period; the registry lists an actual primary completion date of 2026-09-29. Topline results were expected in the fourth quarter of 2026, and no NATiV3 efficacy results were identified. If results are favorable, the company anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. Accelerated approval and conditional authorization, if granted, require completion of the trial for full approval, and a separate event-driven placebo-controlled phase 3 outcome trial in MASH with compensated cirrhosis, expected to last approximately three years, is planned.
- Safety reports: the company reported a treatment-related suspected unexpected serious adverse reaction of elevated liver tests, with biopsy results compatible with autoimmune hepatitis; the participant fully recovered. Screening was paused, the protocol was amended to exclude patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks was added. “Other milder cases of elevation of aminotransferases among trial participants have also been reported.” The Data Monitoring Committee recommended continuing the trial without modification of the protocol.

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf); [Inventiva Fast Track designation release (2019)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-FDA-Fast-Track-EN-26092019-VF.pdf); [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf); [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf); [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf); [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf); [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf); [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf); [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf); [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf)

<a id="topic-1.1.2-2"></a>

##### Summary: NATIVE phase 2b histologic efficacy

NATIVE (NCT03008070) was a phase 2b, double-blind, randomized, placebo-controlled trial in which 247 participants with noncirrhotic, highly active NASH were assigned 1:1:1 to lanifibranor 1200 mg (83), lanifibranor 800 mg (83), or placebo (81) once daily for 24 weeks, with randomization stratified by diabetic status. At baseline, 188 participants (76%) had F2 or F3 fibrosis and 103 (42%) had type 2 diabetes. The primary end point was a decrease of at least 2 points in the SAF-A score without worsening of fibrosis. All biopsy samples were read by one pathologist.

- Primary end point, full analysis population with multiple imputation (the published primary analysis): 55% with 1200 mg, 48% with 800 mg, and 33% with placebo; risk ratio 1.7 (95% CI, 1.2 to 2.3; P=0.007) for 1200 mg and 1.5 (95% CI, 1.0 to 2.1; P=0.07) for 800 mg.
- Primary end point, ITT population in the company topline release: 49% (P=0.004) with 1200 mg, 41% (P=0.061) with 800 mg, and 27% with placebo. In the registry results, which count participants with missing data as nonresponders, 41 of 83, 34 of 83, and 22 of 81 participants responded.
- Secondary histologic end points, multiple imputation: resolution of NASH without worsening of fibrosis in 49%, 39%, and 22% (risk ratios 2.2 and 1.7); improvement in fibrosis of at least 1 stage without worsening of NASH in 48%, 34%, and 29% (risk ratios 1.7, 95% CI 1.2 to 2.5, and 1.2, 95% CI 0.7 to 1.9); and the composite of NASH resolution and fibrosis improvement of at least 1 stage in 35%, 25%, and 9% (risk ratios 4.0 and 2.6), for 1200 mg, 800 mg, and placebo, respectively. No multiplicity adjustments were defined for secondary and exploratory end points.
- The composite end point is the NATiV3 primary composite endpoint. In the ITT analysis of the topline release, it was met by 31% (1200 mg), 21% (800 mg), and 7% (placebo).
- Among the 188 participants with F2 or F3 fibrosis (ITT, topline release), resolution of NASH without worsening of fibrosis occurred in 44% (1200 mg), 34% (800 mg), and 9% (placebo). In the company's investor presentation, effect sizes with lanifibranor for resolution of MASH and improvement of fibrosis were 21% (800 mg) and 26% (1200 mg) in participants with type 2 diabetes and 7% and 22%, respectively, in participants without type 2 diabetes.

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf); [ClinicalTrials.gov NCT03008070 API record](https://clinicaltrials.gov/api/v2/studies/NCT03008070); [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results); [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf); [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-1.1.2-3"></a>

##### Summary: NATIVE liver enzyme, metabolic, and patient-reported results

Among the 228 participants who completed week 24 (77, 77, and 74 for 1200 mg, 800 mg, and placebo), adjusted mean changes from baseline were: alanine aminotransferase −24.54, −26.08, and −1.40 U/liter; glycated hemoglobin −0.41, −0.38, and 0.07 percentage points; fasting triglycerides −0.44, −0.49, and 0.06 mmol/liter; fasting HDL cholesterol 0.11, 0.16, and 0.01 mmol/liter; and adiponectin 17.12, 11.95, and −0.35 μg/ml. LDL cholesterol did not change significantly with either dose versus placebo. Scores on the Enhanced Liver Fibrosis test and the Fibrosis-4 index did not improve. No substantial changes from baseline were observed on the SF-36 or the Flinders Fatigue Scale at week 24. Participants with diabetes had histologic improvements similar to those of the full analysis population and greater reductions in fasting glucose, insulin, and glycated hemoglobin.

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-1.1.2-4"></a>

##### Summary: NATIVE safety, including weight gain, edema, anemia, and discontinuations

In the full analysis population (83 participants receiving 1200 mg, 83 receiving 800 mg, and 81 receiving placebo), with the treatment period extending to 28 days after the last dose:

- Adverse events: at least one adverse event in 62 (75%), 59 (71%), and 50 (62%); severe adverse events in 3 (4%) in each group; serious adverse events in 7 (8%), 3 (4%), and 3 (4%); no deaths. The two serious adverse events assessed as related to study treatment (mild heart failure and urticaria) both occurred with placebo. Diarrhea occurred in 10 (12%), 8 (10%), and 1 (1%), and nausea in 7 (8%), 8 (10%), and 3 (4%).
- Discontinuations: the published report gives discontinuation of the assigned regimen because of adverse events in 3 (4%), 4 (5%), and 3 (4%). The registry participant flow lists adverse events as the reason for not completing in 3, 3, and 3 participants, with one further participant in the 800 mg group listed under withdrawal by patient and adverse event non fatal.
- Weight: weight gain was reported as an adverse event in 7 (8%), 8 (10%), and 0. Mean body weight increased by 2.7 kg (3.1%) with 1200 mg and by 2.4 kg (2.6%) with 800 mg. Cooreman et al. report for the pooled lanifibranor arms an average weight gain of 2.5 kg; at end of treatment, 51% had stable weight (increase of 2.5% or less), 16% an increase of 2.5% to 5%, and 33% an increase of 5% or more, while 84% of placebo participants had stable weight.
- Edema: peripheral edema occurred in 7 (8%), 5 (6%), and 2 (2%). Peripheral edema assessed as related to study drug occurred in four participants receiving lanifibranor (two in each group) and in none receiving placebo; one severe case resolved after the 1200 mg regimen was stopped for 12 days and did not recur when treatment resumed. NT-proBNP increased with both doses (adjusted mean difference versus placebo 8.4 pmol/L with 1200 mg and 4.0 pmol/L with 800 mg), and the authors report no clinical evidence of congestion. The investigator reported nontreatment-related mild heart failure in one participant receiving 1200 mg.
- Anemia: anemia occurred in 6 (7%), 1 (1%), and 0. In the six participants with anemia in the 1200 mg group, hemoglobin returned to pretreatment values after investigator-initiated iron supplementation or discontinuation of lanifibranor. The relative reduction in hemoglobin from baseline was 5 to 6% with lanifibranor and 1% with placebo.
- Kidney function and bone turnover markers were not impaired.

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results); [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-1.1.2-5"></a>

##### Summary: LEGEND and NCT03459079 results

LEGEND (NCT05232071) was a phase 2, three-arm, randomized trial in adults with noncirrhotic MASH and type 2 diabetes (screening HbA1c 7.0% to 10.0%), double-blind for lanifibranor 800 mg and placebo and open-label for lanifibranor 800 mg plus empagliflozin 10 mg, with 24 weeks of treatment. Of 63 planned participants, 39 were treated (12 lanifibranor, 13 combination, 14 placebo); recruitment was stopped after the interim analysis because the primary endpoint was met. The registry lists 12, 12, and 9 completers, and the poster lists 11 completers in the combination arm.

- Primary endpoint, final registry analysis (mixed model for repeated measures): least squares mean change in HbA1c from baseline to week 24 of −1.11 percentage points with lanifibranor (n=11), −1.54 with the combination (n=13), and 0.16 with placebo (n=13); least squares mean differences versus placebo of −1.27 and −1.7 (both p < 0.001).
- Primary endpoint, interim analysis (March 2024, full analysis set of 11, 10, and 9 participants): −1.14, −1.59, and +0.26.
- In the poster, 50% of participants in both active arms reached HbA1c below 6.5% at week 24, and 58% (lanifibranor) and 80% (combination) had an HbA1c decrease of at least 1%, versus 0% with placebo. MRI-PDFF relative changes were −49% and −41%.
- Safety: relative body weight change was 3.6% with lanifibranor, 0.25% with the combination, and −1.16% with placebo. Anemia occurred in 2 of 12, 0 of 13, and 1 of 14 participants, and peripheral edema in 0 of 12, 1 of 13, and 0 of 14. There were no deaths; one serious adverse event (haematuria) occurred in the combination arm. Inventiva does not expect to study the combination further and expects to include the LEGEND safety data in a potential submission for marketing approval.

NCT03459079 was a single-center, double-blind, placebo-controlled, 24-week trial at the University of Florida, financially supported by Inventiva, in which 38 adults with type 2 diabetes and MASLD (intrahepatic triglyceride content of at least 10% by proton magnetic resonance spectroscopy) were randomized to lanifibranor 800 mg (20) or placebo (18). The registry lists an actual enrollment of 128, of whom 38 were randomized. The study did not seek to recruit patients with fibrosis stage F2 or higher, and 28 participants completed it.

- Primary endpoint, absolute change in intrahepatic triglyceride content, full analysis set: −8.7% with lanifibranor and −3.0% with placebo in the published report, and −10.1% and −1.4% in the 2023 congress poster; both report a least squares mean difference of −5.6% (95% CI −9.6 to −1.7%; p = 0.007). The relative change was −44% versus −12%. A reduction of at least 30% occurred in 65% versus 22%, and steatosis resolution (intrahepatic triglyceride content of 5.5% or less) in 25% versus 0%.
- HbA1c changed by −0.7 versus −0.1 percentage points (adjusted least squares mean difference −0.6; p <0.001), and adiponectin increased 2.4-fold with lanifibranor.
- Safety: mean weight change was +2.7% with lanifibranor and −1.0% with placebo. Adverse events led to discontinuation in 4 of 20 (20%) and 2 of 18 (11%), anemia occurred in 4 (20%) and 2 (11%), and edema in 1 (5%) and 0. One serious adverse event under lanifibranor was assessed as unrelated to study drug.

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071); [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf); [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf); [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results); [ClinicalTrials.gov NCT05232071 API record](https://clinicaltrials.gov/api/v2/studies/NCT05232071); [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf); [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext); [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079); [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results); [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="topic-1.1.2-6"></a>

##### Summary: pharmacology, dosing studied, and interaction exclusions

- Mechanism: lanifibranor is designed to activate all three PPAR isoforms, with balanced activation of PPARα and PPARδ and partial activation of PPARγ. Reported EC50 values at human PPARs were 1.63E‐06 M (α), 8.49E‐07 M (δ), and 2.28E‐07 M (γ), with maximal effects of 100% at PPARα and PPARδ and 80% at PPARγ relative to fenofibrate, GW501516, and rosiglitazone, respectively. Kamata et al. state that PPARγ-related effects (weight gain, edema, bone loss, and congestive heart failure) should be closely monitored.
- Dosing studied: 800 mg or 1200 mg once daily as 400 mg film-coated immediate-release tablets taken with food (three tablets daily in NATIVE and NATiV3, with one placebo tablet in the 800 mg arm); doses were selected from adiponectin, HDL cholesterol, and triglyceride results in a phase 2a study in type 2 diabetes. Dose modification was not permitted in NATIVE; LEGEND allowed one interruption of up to 15 days for adverse events. In a QT/QTc study in 217 healthy participants, 1200 and 2400 mg/day did not prolong the QT interval.
- Pharmacokinetics: maximum concentrations at about 1.0 to 3.5 h, terminal half-life of around 10 to 15 h, steady state by day 3 without significant accumulation, and exposure increasing slightly less than dose-proportionally. Plasma protein binding was about 99.9% in all tested species, elimination is mainly faecal (more than 85%) with urinary excretion below 7%, and a food effect was observed with a high-fat breakfast. Cmax was 22% and AUC 39% higher in elderly than in young participants.
- Interactions: in vitro, lanifibranor is metabolized mainly by CYP2C8, CYP2C19, and CYP3A4 and by UGT 2B7, 1A1, and 1A3, and inhibits CYP2C8 (IC50 4 µM), CYP2C9 (8 µM), CYP2C19 (25 µM), and CYP2B6 (8 µM). No significant interaction with simvastatin was observed (less than 2-fold). The LEGEND protocol prohibits strong CYP2C8 inducers (for example, rifampin) and strong CYP2C8 inhibitors (for example, gemfibrozil and clopidogrel), and an amendment driven by preliminary results of drug-drug interaction study 337HVPK21014 also excludes substrates of CYP2B6 and CYP2C8; no published results of that study were identified. NATiV3 excludes concomitant fibrates, thiazolidinediones within 12 months, insulin, and any approved treatment for NASH or obesity, and permits GLP-1 receptor agonists, SGLT2 inhibitors, and statins taken for at least 3 months.
- Trial exclusions relevant to use include hemoglobin below 110 g/L in women or 120 g/L in men, a history of heart failure with reduced ejection fraction, and a diagnosis of or predisposition to autoimmune liver or thyroid disease. The tablets contain lactose monohydrate.

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf); [Wettstein et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5678909/); [Kamata et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10451623/); [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf); [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Lanifibranor

<a id="topic-1.1.3-1"></a>

##### Summary: lanifibranor price and economic evaluations

No price, cost-effectiveness analysis, budget impact analysis, or budget impact model of lanifibranor was identified. Inventiva states that, if lanifibranor is approved, it will still need to “establish a commercially viable pricing structure” and obtain coverage and adequate reimbursement from third-party payors, that market acceptance “will depend significantly on the availability of coverage and adequate reimbursement from third-party payors”, and that it may need to conduct pharmacoeconomic studies to demonstrate cost-effectiveness.

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-1.1.3-2"></a>

##### Summary: comparator prices and their dates

- Resmetirom (Rezdiffra): wholesale acquisition cost of $4,239.38 per 30-tablet package for each strength (60, 80, and 100 mg), stated as accurate as of 10/01/2026; the same package price was stated as of 01/01/2026. At accelerated approval on March 14, 2024, the annual wholesale acquisition cost was reported as $47,400.
- Semaglutide 2.4 mg (Wegovy): list price of $1,349.02 per package. On February 24, 2026, Novo Nordisk announced that, effective January 1, 2027, the list price of Wegovy will be lowered to $675, a reduction of approximately 50%, for all doses.
- A published lifetime cost-effectiveness model used wholesale acquisition cost-based annual treatment costs of $59,268.96 for resmetirom, $16,188.24 for semaglutide, and $13,036.44 for tirzepatide.

Source: [Madrigal Pharmaceuticals Colorado price disclosure (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/10/Resmetirom-Price-Transparency-by-State-Form-Colorado-Oct-2026.pdf); [Madrigal Pharmaceuticals Connecticut price disclosure, January 2026 (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/02/Resmetirom-Price-Transparency-by-State-Form-Connecticut-Jan-2026.pdf); [Joszt (2024)](https://www.ajmc.com/view/fda-approves-resmetirom-first-treatment-for-nash-with-liver-fibrosis); [NovoCare MASH list price (2025)](https://www.novocare.com/mash/resources/explaining-list-price.html); [Novo Nordisk (2026)](https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916505); [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/)

<a id="topic-1.1.3-3"></a>

##### Summary: ICER 2023 assessment of resmetirom

ICER's final evidence report (May 25, 2023) rated resmetirom “C++” compared with standard of care in NASH with F2 or F3 fibrosis. Its Markov model took a health care sector perspective with a lifetime horizon and annual cycles. At an annual placeholder price of $19,000, based on a prior early economic model developed by the manufacturer, resmetirom produced incremental cost savings of approximately $22,400 and approximately 0.60 incremental QALYs compared with standard care alone. Annual prices to reach $50,000, $100,000, $150,000, and $200,000 per QALY gained were $32,100, $39,600, $47,100, and $54,600, and the health benefit price benchmark was $39,600 to $50,100. For budget impact, ICER applied a prevalence of 1.4% to the projected 2023 to 2027 US adult population, assumed that 762,119 patients per year would initiate treatment, and estimated that 6.5% of patients could be treated over five years at the placeholder price before reaching its threshold of approximately $777 million per year; it issued an access and affordability alert. ICER's policy recommendations state that prior authorization is reasonable, that eligible patients include all patients with F2 or F3 fibrosis, that liver biopsy should not be universally required for diagnosis, and that step therapy requiring prior pioglitazone or vitamin E is not reasonable.

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [ICER Final Policy Recommendations, NASH (2023)](https://icer.org/wp-content/uploads/2023/05/NASH_Policy-Recs_Final.pdf)

<a id="topic-1.1.3-4"></a>

##### Summary: published cost-effectiveness results for comparators

- Njei et al. (US payer perspective, state-transition model, F2 to F3 fibrosis): semaglutide $42,200 per QALY at 5 years and $44,138 at 10 years; resmetirom $95,981 per QALY at 5 years and $107,002 at 10 years, each versus standard of care.
- McGovern et al. (US third-party payer perspective, lifetime horizon, 2025 US dollars; model developed under contract with Novo Nordisk): semaglutide 2.4 mg $19,911 per QALY gained, resmetirom 80 mg $346,810, and resmetirom 100 mg $198,607, each versus standard of care.
- Abdeen et al. (US payer perspective, Markov cohort model, lifetime horizon, F2 to F3 fibrosis): tirzepatide $42,705 per QALY, semaglutide $80,076, and resmetirom $273,445; drug price was the most influential parameter.
- Javanbakht et al. (US commercial payer perspective, funded by Madrigal Pharmaceuticals): resmetirom increased costs by US$66,764 and QALYs by 1.24 per patient, for $53,929 per QALY gained, using a daily resmetirom cost of US$52.05.
- Mahady et al. (third-party payer perspective, biopsy-proven NASH with fibrosis level 3 or greater): pioglitazone $A2748 and vitamin E $A8475 per QALY gained versus lifestyle modification alone.
- Younossi et al.: noninvasive-test screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis in the model, had ICERs of $26,913 to $27,884 per QALY in type 2 diabetes and $23,265 to $24,992 per QALY in obesity.

Source: [Njei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13126990/); [McGovern et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13694306/); [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/); [Javanbakht et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9929016/); [Mahady et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22707355/); [Younossi et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39373093/)

<a id="topic-1.1.3-5"></a>

##### Summary: eligible population and budget impact estimates per plan

- A calculator funded by Madrigal Pharmaceuticals estimated 1255 to 1699 resmetirom treatment-eligible adults with noncirrhotic NASH and F2 to F3 fibrosis per 1 million commercial members in years 1 to 3 after approval, using a NASH prevalence of 4.6%, a 35% proportion with noncirrhotic moderate-to-advanced fibrosis, a diagnosis rate of about 10%, and about 16% annual growth in the treatment-eligible population.
- A budget impact analysis funded by Madrigal Pharmaceuticals for a hypothetical one-million-member US private plan, using the March 2024 resmetirom wholesale acquisition cost and uptake of 4%, 8%, and 14% of treatment-eligible patients, estimated 50, 117, and 238 patients treated in years 1 to 3, a net budget impact of $2.2 to $9.5 million, and $0.19 to $0.80 per member per month.
- An NHANES 2017 to March 2020 analysis estimated that 8.3 million (95% CI 6.6 to 9.9 million) US adults met liberal and 2.3 million (95% CI 1.4 to 3.2 million) met restrictive resmetirom eligibility criteria.

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [Fishman et al. (2024a)](https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2393952); [Le et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180822/)

<a id="topic-1.1.3-6"></a>

##### Summary: health-state utility weights

- ICER 2023 model, derived from the GAIN study: 0.76 for NASH fibrosis stages 0 to 2, 0.73 for stage 3, and 0.66 for compensated cirrhosis.
- GAIN study, US respondents with biopsy-confirmed NASH: mean EQ-5D index 0.80 for early (F0 to F2) and 0.67 for advanced (F3 to F4) fibrosis.
- Abdeen et al. model inputs from an EQ-5D-5L and discrete choice experiment elicitation study: 0.671 for MASH F2 and 0.605 for MASH F3.
- ESSENCE part 1 (sponsored by Novo Nordisk): baseline mapped EQ-5D utility of approximately 0.78 in adults with MASH and F2 or F3 fibrosis.
- 883 participants with noncirrhotic MASH (62% F3): mean estimated EQ-5D of 0.851 from the CLDQ-NAFLD-based algorithm and 0.853 from the SF-36-based algorithm.
- SF-6D: 0.660 in noncirrhotic and 0.551 in cirrhotic NAFLD.

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/); [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/); [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/); [Younossi et al. (2025d)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12277723/); [Sayiner et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5013331/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary: disease burden in MASH with F2 to F3 fibrosis

The 2023 AASLD practice guidance refers to NASH with at least stage 2 fibrosis as at-risk NASH, with a higher risk of liver-related morbidity and mortality. In 14 articles of cohort studies involving 17,301 patients with biopsy-proven NAFLD, all-cause mortality hazard ratios compared with stage 0 were 1.46 for stage 2 and 1.96 for stage 3, and liver-related mortality hazard ratios were 4.07 and 7.59. In a cohort analysis supported by Novo Nordisk Inc., incidence rates of cirrhosis were 1.24/100PM for F2 and 6.62/100PM for F3, and in a cohort of 1,260 patients with NAFLD without cirrhosis the 20-year cumulative incidence of major adverse liver outcomes was 35% for F3. A pooled analysis of 54 studies estimated the time to progress by one fibrosis stage at 13.3 years from F2 and 22.2 years from F3.

US population estimates depend on the model. An eligible-population model applied a NASH prevalence of 4.6% (range 1.3% to 14.2%) and a non-cirrhotic F2 to F3 proportion of 35%; the ICER budget impact analysis applied a prevalence of 1.4% to US adults, an average of 3.81 million eligible patients; and another model projected cases of MASH with F2 or higher fibrosis to increase from 6.7 million in 2020 to 11.7 million by 2050. A diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population has been estimated, and NHANES survey responses indicate that 14.3% of prevalent patients with F2 to F3 NASH have received a diagnosis of liver disease. In the GAIN study, mean EQ-5D index values among US respondents were 0.80 for early (F0 to F2) and 0.67 for advanced (F3 to F4) fibrosis. The ICER model used annual health care costs of $7,063 for F0 to F2 and $8,423 for F3.

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/); [Luthra and Sheth (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11787050/); [Akbari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10827505/); [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/); [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [Le et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742522/); [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-1.1.4-2"></a>

##### Summary: lanifibranor phase 2 efficacy and safety

The histologic evidence on lanifibranor comes from NATIVE (NCT03008070), a 24-week phase 2b trial in which 247 participants with noncirrhotic, highly active NASH were randomized to lanifibranor 1200 mg (83), lanifibranor 800 mg (83), or placebo (81); 188 participants (76%) had F2 or F3 fibrosis, and all biopsy samples were read by one pathologist. The primary end point (a decrease of at least 2 points in the SAF-A score without worsening of fibrosis) is reported with three analyses:

- Full analysis population with multiple imputation (the published primary analysis): 55% with 1200 mg, 48% with 800 mg, and 33% with placebo (P=0.007 for 1200 mg and P=0.07 for 800 mg).
- ITT population in the company topline release: 49% (P=0.004), 41% (P=0.061), and 27%.
- Registry results counting missing data as nonresponse: 41 of 83, 34 of 83, and 22 of 81 responders. The protocol's primary rule counted missing data as nonresponse, and week 24 biopsies were missing for 34 participants.

With multiple imputation, resolution of NASH without worsening of fibrosis occurred in 49%, 39%, and 22%, and improvement in fibrosis of at least 1 stage without worsening of NASH in 48%, 34%, and 29%. The composite of NASH resolution and fibrosis improvement, which is the NATiV3 primary composite endpoint, occurred in 35%, 25%, and 9% with multiple imputation and in 31%, 21%, and 7% in the ITT topline analysis. No multiplicity adjustments were defined for secondary and exploratory end points. An analysis of 29 randomized controlled trials reported a risk ratio of 1.93 (CrI 1.30 to 3.02) for lanifibranor versus placebo for MASH resolution without worsening fibrosis, based mostly on indirect comparisons. The primary endpoint of LEGEND (39 participants with type 2 diabetes treated for 24 weeks) was the change in HbA1c, and that of NCT03459079 (38 participants with type 2 diabetes and MASLD) was the change in intrahepatic triglyceride content.

Safety figures in NATIVE (1200 mg, 800 mg, placebo) were: serious adverse events 7 (8%), 3 (4%), and 3 (4%), with no deaths; diarrhea 10 (12%), 8 (10%), and 1 (1%); weight gain reported as an adverse event in 7 (8%), 8 (10%), and 0, with mean body weight increases of 2.7 kg (3.1%) with 1200 mg and 2.4 kg (2.6%) with 800 mg; peripheral edema in 7 (8%), 5 (6%), and 2 (2%); and anemia in 6 (7%), 1 (1%), and 0. Discontinuations for adverse events were 3 (4%), 4 (5%), and 3 (4%) in the journal report and 3, 3, and 3 in the registry participant flow. In LEGEND, relative body weight change was 3.6% with lanifibranor alone, and in NCT03459079 mean weight change was +2.7% with lanifibranor and −1.0% with placebo, with anemia in 4 of 20 (20%) and 2 of 18 (11%). In NATiV3, a treatment-related suspected unexpected serious adverse reaction of elevated liver tests with biopsy results compatible with autoimmune hepatitis led to a pause in screening, a protocol amendment excluding patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks. The manufacturer's Form 20-F states that weight gain with lanifibranor may lead patients to prefer a GLP-1 agent for the treatment of MASH.

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf); [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results); [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf); [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf); [Souza et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12614381/); [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071); [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf); [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext); [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf); [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-1.1.4-3"></a>

##### Summary: evidence not available until NATiV3 reports, and the regulatory path

Lanifibranor “has not been approved for use by any regulatory authority”, and no price, proposed labeling, or commercial dose was identified. NATiV3 (NCT04849728) randomized adults with biopsy-proven noncirrhotic MASH and F2 or F3 fibrosis 1:1:1 to lanifibranor 800 mg or 1200 mg once daily or placebo for 72 weeks. All participants had completed the 72-week treatment period, the registry lists an actual primary completion date of 2026-09-29, and topline results were expected in the fourth quarter of 2026; no NATiV3 efficacy results were identified. Until it reports, the following remain unknown or differ by source:

- Efficacy in the F2 to F3 population at 72 weeks, and in a main cohort in which 67.0% had F3 fibrosis, 55% had type 2 diabetes, 14.0% were taking a GLP-1 receptor agonist, and 10.0% an SGLT2 inhibitor at baseline, compared with 42% type 2 diabetes and 0.0% GLP-1 receptor agonist use in NATIVE in the same slides.
- The endpoints that will support a submission: the registry and the investor and analyst day presentation name the composite of NASH resolution and fibrosis improvement as primary, and the Form 20-F financing terms name the two single histologic endpoints.
- The number analyzed: 1,009 participants in the main cohort and 410 in an exploratory cohort (company), an estimated enrollment of 1000 (registry), and approximately 950 patients for the NDA analysis (Form 20-F).
- Unblinded safety: at one Data Monitoring Committee review, the data were unblinded to the committee and remained blinded with respect to the company, and the committee recommended continuing the trial without modification of the protocol.
- Drug interactions: an amendment driven by preliminary results of drug-drug interaction study 337HVPK21014 excludes substrates of CYP2B6 and CYP2C8, and no published results of that study were identified.

If results are favorable, the company anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. The FDA has granted lanifibranor Breakthrough Therapy and Fast Track designation for the treatment of MASH. Accelerated approval, if granted, requires completion of the trial for full approval, and a separate event-driven phase 3 outcome trial in MASH with compensated cirrhosis, expected to last approximately three years, is planned. The EASL guideline states that agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes.

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf); [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf); [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf); [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-1.1.4-4"></a>

##### Summary: approved comparators and economic evidence

Resmetirom and semaglutide 2.4 mg are approved for noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3), both under accelerated approval based on improvement of MASH and fibrosis. In the resmetirom label's month 12 analysis of 888 F2 and F3 patients, with missing biopsies counted as nonresponse, resolution of steatohepatitis without worsening of fibrosis occurred in 27% (80 mg) and 36% (100 mg) versus 13% with placebo by Pathologist A, and 26% and 24% versus 9% by Pathologist B. In the semaglutide label's week 72 analysis of 800 F2 and F3 patients, with reference-based multiple imputation, resolution of steatohepatitis without worsening of fibrosis occurred in 63% versus 34%, and improvement in liver fibrosis without worsening of steatohepatitis in 37% versus 22%. No head-to-head trial of lanifibranor with either agent has been conducted, and resmetirom and semaglutide have not been studied in combination or compared. Pioglitazone and vitamin E are not FDA approved for MASH.

No price, cost-effectiveness analysis, or budget impact analysis of lanifibranor was identified. The comparators have published prices: resmetirom has a wholesale acquisition cost of $4,239.38 per 30-tablet package for each strength as of October 1, 2026, and semaglutide 2.4 mg has a list price of $1,349.02 per package, which Novo Nordisk announced will be lowered to $675, effective January 1, 2027. ICER's May 2023 assessment rated resmetirom “C++” compared with standard of care, set a health-benefit price benchmark of $39,600 to $50,100, and issued an access and affordability alert. Published US analyses report incremental cost-effectiveness ratios that vary by study: for semaglutide, $19,911 to $80,076 per QALY, and for resmetirom, $53,929 to $346,810 per QALY, with drug price the most influential parameter in one model. A Madrigal-funded budget impact analysis for a hypothetical one-million-member US private plan estimated a resmetirom net budget impact of $2.2 to $9.5 million over years 1 to 3, or $0.19 to $0.80 per member per month. Published utility weights for these health states include 0.76 (F0 to F2) and 0.73 (F3) in the ICER model, and 0.671 (MASH F2) and 0.605 (MASH F3) in another model.

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf); [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf); [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Madrigal Pharmaceuticals Colorado price disclosure (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/10/Resmetirom-Price-Transparency-by-State-Form-Colorado-Oct-2026.pdf); [NovoCare MASH list price (2025)](https://www.novocare.com/mash/resources/explaining-list-price.html); [Novo Nordisk (2026)](https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916505); [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [Njei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13126990/); [McGovern et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13694306/); [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/); [Javanbakht et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9929016/); [Fishman et al. (2024a)](https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2393952)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
